34
Views
10
CrossRef citations to date
0
Altmetric
Research Article

Acute Overdosage of Amiodarone in a Suicide Attempt

, , , &
Pages 181-186 | Published online: 25 Sep 2008
 

Abstract

Clinical and biochemical variables and blood levels of amiodarone and its metabolite are reported after acute self-intoxication in a young woman. Despite the huge amount of drug ingested no clinical side effects were documented over the monitored period of 3 months.

Amiodarone, a benzofuran derivative with a chemical structure resembling thyroxine, was marketed twenty years ago for the treatment of angina pectoris(l). A decade after its introduction in clinical medicine, its activity in supraventricular and ventricular tachyarrhythmias has been recoqnized (2). Data on the clinical benefits of amiodarone have been accumulating rapidly and consistently, but its acute and chronic toxicological profile is far from adequately understood, possibly because of the lack of systematic studies and the wide range of doses adopted by various authors (400 to 2000 mg/day loading dose; 200-800 mg/day maintenance dose) (3-6). In particular, apart from rare studies on i.v. administration (7), the acute adverse effects of the drug have received no specific attention. In the case reported here the non-therapeutic acute ingestion of a large amount of amiodarone represents an extreme situation with potential clinical interest.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.